AAAAAA
Results:
1-21
|
Results: 21
Authors:
Foli, A
Benvenuto, F
Piccinini, G
Bareggi, A
Cossarizza, A
Lisziewicz, J
Lori, F
Citation: A. Foli et al., Direct analysis of mitochondrial toxicity of antiretroviral drugs, AIDS, 15(13), 2001, pp. 1687-1694
Authors:
Lisziewicz, J
Gabrilovich, DI
Varga, G
Xu, JQ
Greenberg, PD
Arya, SK
Bosch, M
Behr, JP
Lori, F
Citation: J. Lisziewicz et al., Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells, J VIROLOGY, 75(16), 2001, pp. 7621-7628
Authors:
Lori, F
Lisziewicz, J
Citation: F. Lori et J. Lisziewicz, Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug, CLIN INF D, 30, 2000, pp. S193-S197
Authors:
Lisziewicz, J
Zeng, G
Gratas, C
Weinstein, JN
Lori, F
Citation: J. Lisziewicz et al., Combination gene therapy: Synergistic inhibition of human immunodeficiencyvirus Tat and Rev functions by a single RNA molecule, HUM GENE TH, 11(6), 2000, pp. 807-815
Authors:
Lori, F
Lisziewicz, J
Citation: F. Lori et J. Lisziewicz, Role of immune modulation in primary HIV infection, J BIOL REG, 14(1), 2000, pp. 45-48
Authors:
Ravot, E
Tambussi, G
Jessen, H
Tinelli, C
Lazzarin, A
Lisziewicz, J
Lori, F
Citation: E. Ravot et al., Effects of hydroxyurea on T cell count changes during primary HIV infection, AIDS, 14(5), 2000, pp. 619-622
Authors:
Lori, F
Maserati, R
Foli, A
Seminari, E
Timpone, J
Lisziewicz, J
Citation: F. Lori et al., Structured treatment interruptions to control HIV-1 infection, LANCET, 355(9200), 2000, pp. 287-288
Authors:
Lori, F
Lewis, MG
Xu, JQ
Varga, G
Zinn, DE
Crabbs, C
Wagner, W
Greenhouse, J
Silvera, P
Yalley-Ogunro, J
Tinelli, C
Lisziewicz, J
Citation: F. Lori et al., Control of SIV rebound through structured treatment interruptions during early infection, SCIENCE, 290(5496), 2000, pp. 1591-1593
Authors:
Lori, F
Lisziewicz, J
Citation: F. Lori et J. Lisziewicz, Hydroxyurea: overview of clinical data and antiretroviral and immunomodulatory effects, ANTIVIR TH, 4, 1999, pp. 101-108
Authors:
Finzi, D
Blankson, J
Siliciano, JD
Margolick, JB
Chadwick, K
Pierson, T
Smith, K
Lisziewicz, J
Lori, F
Flexner, C
Quinn, TC
Chaisson, RE
Rosenberg, E
Walker, B
Gange, S
Gallant, J
Siliciano, RF
Citation: D. Finzi et al., Latent infection of CD4(+) T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy, NAT MED, 5(5), 1999, pp. 512-517
Authors:
Seminari, E
Lisziewicz, J
Tinelli, C
Foli, A
Lori, F
Maserati, R
Citation: E. Seminari et al., Hydroxyurea toxicity combined with didanosine (ddl) in HIV-1-seropositive asymptomatic individuals, INT J CL PH, 37(10), 1999, pp. 514-518
Authors:
Lori, F
Jessen, H
Lieberman, J
Clerici, M
Tinelli, C
Lisziewicz, J
Citation: F. Lori et al., Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir), AIDS RES H, 15(7), 1999, pp. 619-624
Authors:
Lori, F
Rosenberg, E
Lieberman, J
Foli, A
Maserati, R
Seminari, E
Alberici, F
Walker, B
Lisziewicz, J
Citation: F. Lori et al., Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters, AIDS RES H, 15(15), 1999, pp. 1333-1338
Authors:
Lori, F
Lisziewicz, J
Citation: F. Lori et J. Lisziewicz, Mechanisms of human immunodeficiency virus type 1 inhibition by hydroxyurea, J BIOL REG, 13(3), 1999, pp. 176-180
Authors:
Lieberman, J
Trimble, LA
Friedman, RS
Lisziewicz, J
Lori, F
Shankar, P
Jessen, H
Citation: J. Lieberman et al., Expansion of CD57 and CD62L(-)CD45RA(+) CD8 T lymphocytes correlates with reduced viral plasma RNA after primary HIV infection, AIDS, 13(8), 1999, pp. 891-899
Authors:
Lisziewicz, J
Rosenberg, E
Lieberman, J
Jessen, H
Lopalco, L
Siliciano, R
Walker, B
Lori, F
Citation: J. Lisziewicz et al., Control of HIV despite the discontinuation of antiretroviral therapy, N ENG J MED, 340(21), 1999, pp. 1683-1684
Authors:
Boyer, PL
Lisziewicz, J
Lori, F
Hughes, SH
Citation: Pl. Boyer et al., Analysis of amino insertion mutations in the fingers subdomain of HIV-1 reverse transcriptase, J MOL BIOL, 286(4), 1999, pp. 995-1008
Authors:
Lori, F
Jessen, H
Lieberman, J
Finzi, D
Rosenberg, E
Tinelli, C
Walker, B
Siliciano, RF
Lisziewicz, J
Citation: F. Lori et al., Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir, J INFEC DIS, 180(6), 1999, pp. 1827-1832
Authors:
Ravot, E
Lisziewicz, J
Lori, F
Citation: E. Ravot et al., New uses for old drugs in HIV infection - The role of hydroxyurea, cyclosporin and thalidomide, DRUGS, 58(6), 1999, pp. 953-963
Authors:
Lori, F
Lisziewicz, J
Citation: F. Lori et J. Lisziewicz, Hydroxyurea: mechanisms of HIV-1 inhibition, ANTIVIR TH, 3, 1998, pp. 25-33
Authors:
Lori, F
Lisziewicz, J
Citation: F. Lori et J. Lisziewicz, Cellular factors: targets for the treatment of HIV infection, ANTIVIR TH, 3, 1998, pp. 81-92
Risultati:
1-21
|